Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MLNR | O43193 | 1/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8836872 | 0.83 | BRS3 (0.33) | PPARGCYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL9291479 | 0.83 | PARP1 (0.35) | PPARGCYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL844427 | 0.82 | ABCB11 (0.38) | PPARGCYP3A4ADORA3ADRA2BSLC6A2 | |
| Candesartan Cilexetil SCHEMBL1021483 | 0.79 | NAE1 (0.79) | PPARGKDM4EMEN1MLNRNR1I2 | |
| Candesartan Cilexetil SCHEMBL40831 | 0.79 | NAE1 (0.79) | PPARGKDM4EMEN1MLNRNR1I2 | |
| Candesartan Cilexetil SCHEMBL3968703 | 0.79 | NAE1 (0.79) | PPARGKDM4EMEN1MLNRNR1I2 | |
| Candesartan Cilexetil SCHEMBL16949997 | 0.79 | NAE1 (0.79) | PPARGKDM4EMEN1MLNRNR1I2 | |
| Candesartan Cilexetil SCHEMBL6515280 | 0.78 | NAE1 (0.78) | PPARGKDM4EMEN1MLNRNR1I2 | |
| SCHEMBL12181757 | 0.78 | PPARG (0.67) | PPARGKDM4EMEN1MLNRNR1I2 | |
| SCHEMBL9197579 | 0.78 | KDM4E (0.66) | PPARGKDM4EMEN1MLNRNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253327-A1 | Pharmaceutical composition containing a compound having angiotensin II antagonistic activity in combination with another compound | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| EP-1306089-B1 | Combination of benzimidazoles having angiotensin-II antagonistic activity with diuretics | TAKEDA PHARMACEUTICAL (JP) | 2007-09-05 | — | — | EP | disclosed |
| EP-1813286-A2 | Pharmaceutical composition containing a compound having angiotensin II antagonistic activity in combination with another compound | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-0914158-B2 | PHARMACEUTICAL COMBINATION CONTAINING A COMPOUND HAVING ANGIOTENSIN II ANTAGONISTIC ACTIVITY AND A COMPOUND WHICH INCREASES THE INSULIN-SENSITIVITY | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-01-25 | — | — | EP | disclosed |
| US-20040219208-A1 | Sustained-release medicines | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-04 | — | — | US | disclosed |
| US-6432996-B1 | ADMINISTERING BENZIMIDAZOLE DERIVATIVE ANGIOTENSIN II ANTAGONIST, INDANE DERIVATIVE ANGIOTENSIN CONVERTING ENZYME INHIBITOR, AND PYRIDINE DERIVATIVE HMG-CO A REDUCTASE INHIBITOR TO TREAT PROSTPRANDIAL HYPERGLYCEMIA IN DIABETES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-08-13 | — | — | US | disclosed |
| EP-0914158-B1 | PHARMACEUTICAL COMBINATION CONTAINING A COMPOUND HAVING ANGIOTENSIN II ANTAGONISTIC ACTIVITY AND A COMPOUND WHICH INCREASES THE INSULIN-SENSITIVITY | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-07-10 | — | — | EP | disclosed |
| EP-1192951-A2 | Pharmaceutical composition containing a compound having angiotensin II antagonistic activity in combination with another compound | Takeda Chemical Industries, Ltd. (JP) | 2002-04-03 | — | — | EP | disclosed |
| US-6107323-A | PREVENTING OR TREATING ANGIOTENSIN DISEASES BY ADMINISTERING AN ANTAGONIST AND COMPOUND WHICH INCREASES INSULIN SENSITIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-08-22 | — | — | US | disclosed |
| EP-0914158-A2 | PHARMACEUTICAL COMBINATION CONTAINING A COMPOUND HAVING ANGIOTENSIN II AND ANTAGONISTIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 1999-05-12 | — | — | EP | disclosed |
| WO-1997037688-A2 | PHARMACEUTICAL COMBINATION CONTAINING A COMPOUND HAVING ANGIOTENSIN II AND ANTAGONISTIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040219208-A1 | Sustained-release medicines | ACE, AGTR2, AGT | PPARG 875/4885KDM4E 2132/4885MEN1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.